Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lu Daopei Medical

Request full access

Renowned hematology specialist and pioneer of Chinese bone marrow transplantation

Dongcheng District, ChinaFounded 2001Biotech & Life Sciences

About Lu Daopei Medical

Lu Daopei Medical Group is a private healthcare provider in China specializing in hematology. The company was founded in 2012 by Professor Lu Daopei, a globally recognized hematologist and an academician of the Chinese Academy of Engineering, who is considered a pioneer in blood disease treatment and hematopoietic stem cell transplantation (HSCT) in the region. Professor Lu, born in 1931, dedicated his career to hematology after graduating from Tongji Medical College in 1955. His journey includes performing Asia's first syngeneic bone marrow transplant in 1964 and China's first allogeneic bone marrow transplant in 1981, establishing him as a foundational figure in the field. The medical group was the culmination of his life's work, established when he was in his eighties to focus on the treatment, research, and teaching of hematology and oncology. The company is now controlled by his grandson, Lu Xiaodan.

The group operates a network of specialist hospitals, including Hebei Yanda Lu Daopei Hospital, Beijing Lu Daopei Hospital Yizhuang Campus, and Beijing Lu Daopei Hospital Shunyi Campus. Expansion plans include a new hospital in Shanghai and the relocation and expansion of the Hebei facility. As of 2022, Lu Daopei Medical was the largest hematology medical service provider in China by revenue, holding a 6.4% market share. The company's business model is centered on providing comprehensive, full-cycle medical services for blood diseases. Revenue is generated from general hospital services—both inpatient and outpatient—and specialized hematological examination services. The primary source of income is inpatient services, which account for over 70% of total revenue. Its target clients are patients diagnosed with hematological disorders, including complex and refractory cases, for whom HSCT is often a crucial treatment option.

Lu Daopei Medical offers a wide array of treatments, including HSCT, chemotherapy, targeted therapy, and immunotherapy, with a significant focus on bone marrow transplants. The group is particularly noted for its high volume of HSCT procedures, completing 8,966 transplants by September 2023, the majority being the complex allogeneic and haploidentical types. This specialization makes it the second-largest HSCT participant in China. A key service is its advanced CAR-T cell therapy, positioning the hospital as a leading center for this treatment globally. The hospitals are equipped with advanced medical and laboratory equipment, including numerous clean rooms for transplant patients. The company also provides its specialized testing services to over 100 other hospitals in China.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
24.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2C

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jul 2020 $72M $288M Investcorp · Temasek —
FundingOther financing Jan 2014 $0 — CBC Group ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Lu Daopei Medical website traffic

Latest recorded traffic for Lu Daopei Medical is 210 monthly website visits, down 61.8% over the last three months.

Latest monthly visits210 3-month web change-61.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Lu Daopei Medical in the Dongcheng District ecosystem

Live from Dealroom

The Lu Daopei Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Other known investors1 additional known investor

  • CBC Group
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Dongcheng District HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lu Daopei Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lu Daopei Medical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.